



Recent Advances in Ocular Drug Delivery

Guest Editors:

Dr. Sven Schnichels

Centre for Ophthalmology,
University Eye Hospital Tübingen,
Tübingen, Germany

Dr. Miguel González-Andrades

1. Maimonides Biomedical
Research Institute of Cordoba
(IMIBIC), Department of
Ophthalmology, Reina Sofia
University Hospital and
University of Cordoba, 14004
Cordoba, Spain
2. Department of
Ophthalmology, Massachusetts
Eye and Ear and Schepens Eye
Research Institute, Harvard
Medical School, Boston, MA
02114, USA

Deadline for manuscript
submissions:

closed (30 April 2022)

Message from the Guest Editors

Dear Colleagues,

Eye diseases are either treated with eye drops or, more rarely, systemically with intravitreal injections. However, the treatment efficacy of eye drops is low because only 1–5% of the administered drug remains in the eye long enough to be effective. For retinal diseases, this percentage drops down to less than 1% due to low ocular penetration. Therefore, repeated intravitreal injections are needed to treat retinal diseases, which can result in side effects and systemic spreading. Hence, more robust drug delivery systems need to be developed in order to avoid unwanted side effects and achieve better therapeutic outcomes. Nano- and microparticles offer great opportunities to overcome these challenges.

This Special Issue aims to capture the current state-of-the-art advances in ocular drug delivery. Suggested topics include the following: novel micro- and nanoparticles; improvements in implantable devices and slow release systems; new approaches in targeted ocular drug delivery; and challenges and obstacles of ocular drug delivery (systems).





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma